will be constant, regardless of the administration schedule. Administering the daily dose via large individual doses at longer intervals will result in high peak concentrations but smaller T>MIC values. The opposite will occur when smaller doses are administered more frequently. The differences observed with different dosing schemes will be most marked for drugs with short half-lives. Measurement of one or more of these values (AUC, peak, T>MIC) may be important in individualizing dosing regimens of certain antimicrobials.
Pharmacodynamic properties of drugs are concerned with the relationship between concentration and some effect. In the case of antibiotics, this usually involves the relationships between concentration and antimicrobial activity or toxicity. The pharmacodynamic parameters most often used to characterize antimicrobial activity are the MIC and the minimum bactericidal concentration (MBC). Unfortunately, these measures of activity are inadequate to completely characterize an antibiotic's pharmacodynamic properties. The MIC and MBC reflect net drug effect following a fixed time of incubation of drug and organism and are often viewed as "all or none" (growth versus no growth, killing versus no killing) phenomena. These parameters, therefore, do not account for the time course of antimicrobial activity. For example, use of the MIC as an endpoint obscures the fact that a substantial proportion of a population of bacteria may be inhibited or killed at concentrations below this value. The MBC does not reflect the rate at which bacteria are killed, and does not offer insight as to whether or not bactericidal activity is further enhanced at higher concentrations. Furthermore, MICs and MBCs are determined after exposure to As was mentioned previously, design of antimicrobial dosing regimens should integrate both the pharmacokinetic and pharmacodynamic properties of the agent in question. The use of the MIC and MBC as the only measures of antimicrobial activity has led to two generalizations in dosing regimen design. One is that in order to achieve an optimal therapeutic effect, antibiotic concentrations must exceed the MIC for the majority of the dosing interval to prevent organism regrowth. In fact, it has been demonstrated by many investigators that for certain antibiotic/pathogen pairs, growth of organisms does not resume immediately after antibiotic concentrations have declined to sub-MIC levels. This phenomenon has been termed the postantibiotic effect (PAE).2-6 The PAE is therefore another important pharmacodynamic parameter to consider in dosing regimen design, and one not directly related to the MIC or MBC.
Another generalization applied to the design of antimicrobial dosing regimens has been that an increase in drug concentration will invariably result in greater antibacterial activity. This has led to the use of measures such as the serum concentration:MIC ratio and serum bactericidal titer (SBT) to estimate the relative in vivo activity of antimicrobials and to predict their clinical efficacy.7-10 Different classes of antimicrobials often are compared in this respect, despite evidence that the relationship between antibiotic concentration and bactericidal activity may not be linear for all drugs. A number of published reports demonstrate a correlation between higher antibiotic serum concentrations and increased efficacy.11-17 However, these reports fail to consider the interdependence of the aforementioned pharmacokinetic parameters, each of which may influence outcome. For example, while higher concentration:MIC ratios may be achieved in patients who were treated successfully, the T>MIC is also likely to be greater in these patients. One is therefore unable to retrospectively determine if the favorable outcome was because of high serum antibiotic concentrations, longer periods of antibacterial activity or both. Characterization of the concentration/bactericidal activity relationship of an antibiotic may offer insight into determining which parameter is most important.
PAE
The PAE is usually defined as the difference in the time required for the number of organisms previously exposed to an antibiotic to increase by tenfold minus the time for control organisms to increase by a similar amount. In cases where a PAE would be expected (Table) , transient sub-MIC levels that occur as a result of infrequent dosing would not be expected to cause a reduction in efficacy. On the other hand, serum concentrations continuously in excess of the MIC would appear to be desirable for p-lactams against gram-negative bacilli, as almost no PAE is observed in these cases.
In addition, because the bactericidal rate of p-lactam antibiotics is saturable with respect to concentration, it would appear to be more important to maximize the duration of time for which concentrations exist at the saturation level (i.e., T>MIC) rather than the intensity of exposure, because increasing concentrations above this saturation level would show no benefit. Therefore, the most "efficient" method for administering a given daily dose of a p-lactam would be to divide the dose into smaller units and employ administration at short enough intervals to ensure continuous antibacterial activity. The ultimate extension of this would be continuous infusion of drugs. In particular, p-lactam antibiotics with short serum halflives would be expected to be more efficacious when dosed in this fashion.
In contrast, for drugs exerting a concentrationdependent bactericidal activity, such as aminoglycosides and quinolones, both the duration and intensity of exposure would appear to be important in determining efficacy. Dosing by continuous infusion would yield a constant effect over time, whereas a bolus injection would yield a greater early bactericidal effect and a smaller late effect. Although the net effect for both means of administration would be expected to be similar over the period for which active levels of drug exist in serum, intermittent injections yielding higher initial peak concentrations may be preferable to ensure activity against any less-susceptible subpopulations of bacteria in infected foci. In fact, emergence of low-level resistance may be encountered during therapy with aminoglycosides and quinolones, which supports the use of less-frequent administration of large doses.
In contrast with therapeutic effects, the rate of renal cortical uptake for aminoglycosides, a prerequisite for nephrotoxicity, appears to be saturable with respect to concentration.27-29 Similar results have been observed for the rate of uptake of aminoglycosides into the endolymph of the inner ear.29 To theoretically minimize nephro-and ototoxicity, one should therefore administer the entire daily dose as a single injection to minimize exposure time. Avoidance of toxicity provides additional incentive for less-frequent administration of aminoglycosides.
INFLUENCE OF DOSING REGIMENS ON ANTIBIOTIC EFFICACY
Investigators have employed a variety of methods by which to study the effect of dosing regimen on the antibiotic-pathogen interaction. The most common methodology has been the direct comparison of different dosing schedules in in vitro dilution models and in the treatment of infections in animals and humans. In addition, attempts have been made to characterize specific laboratory parameters that determine the outcome of treatment of infections. Each of these methods has inherent advantages and disadvantages in its application. The role of dosing regimen in determining the efficacy of antibiotics as it pertains to each method will be discussed separately for 13-lactams and for aminoglycosides and quinolones.
p-lactams: In Vitro Models
Numerous in vitro models have been developed to study the activity of antimicrobials using fluctuating concentrations similar to those observed in vivo. However, few of these studies varied dosing regimens to examine the impact of pharmacokinetic and pharmacodynamic properties of antibiotics on therapeutic outcome.30-35 Grasso modified the peak concentration and elimination half-life of cefazolin to determine the impact of each on the rate and extent of bactericidal activity against Escherichia coli and Klebsiella pneumoniae.3o Increasing peak concentrations exerted little influence on the extent of bactericidal activity, consistent with observations of others that 13-lactams do not exhibit concentration-dependent bactericidal activity. However, increasing the half-life (and therefore the duration of exposure to active drug concentrations) resulted in a pronounced increase in bactericidal effect. These observations were confirmed in a later study with ampicillin against E coli by White and Toothaker.33 Klaus and associates reported no difference in efficacy between simulated concentrations of amoxicillin (750 mg given three times daily and 1000 mg twice daily against E coli). 34 The two regimens were comparable in the amount of time concentrations exceeded the MIC, although both allowed regrowth of resistant subpopulations of bacteria.
Zinner and colleagues studied the impact of dose and dose interval of cefoperazone in an in vitro capillary model using four different bacterial strains.35 At a total daily dose of 4 g, cefoperazone was equally effective against E coli and K pneumoniae whether given as a single daily dose or divided and given every 12 hours. Because of the exquisite sensitivity of these two strains to cefoperazone, concentrations in this model were in excess of the MIC for over 20 hours for both regimens. In contrast, when tested against less-sensitive Staphylococcus aureus and Pseudomonas aeruginosa, the divided dose regimen was much more effective in preventing regrowth of resistant organisms because of more marked differences in T>MIC between the two regimens.
13-lactams: Animal Models
Many studies of antimicrobial efficacy have been performed in animals to characterize the impact of dosing frequency on therapeutic outcome.35-48 Experimental designs that vary the total daily dose, dosing interval and (to a lesser extent) organism susceptibility of antibiotics must be used to independently vary the pharmacokinetic parameter's AUC, peak level and T>MIC in order to determine which parameter(s) are important for outcome. Early studies by Eagle and colleagues concluded that the aggregate time active concentrations were maintained in serum was the most important determinant of efficacy for penicillin G.36 ' Bakker-Woudenberg and colleagues, using a similar model in neutropenic rats, showed the dose of drug protecting 50% of infected animals from death was higher for p-lactams when administered at intermittent schedules than by continuous infusion.43-45 Continuous infusion or frequent dosing of p-lactams has also resulted in improved efficacy over intermittent injection in animal models of peritonitis and endocarditis.46-48
13-lactams: Studies in Humans
The goals of pharmacodynamic studies of antibiotics in humans should be to confirm the impact of dosing frequency of antibiotics that has been observed in animal studies, to determine what (if any) laboratory test(s) should be used to adjust dosing regimens in order to increase the likelihood of efficacy and to determine what the critical value for this test(s) should be.
Schentag and colleagues analyzed the role of pharmacokinetic parameters (AUC, T>MIC, peak level) in predicting efficacy of cefmenoxime in treating nosocomial bacterial pneumonia. 49 In this study, the cefmenoxime AUC was reported as being the most important parameter correlating with eradication of pathogens, but the correlation with T>MIC was equally as strong. A subset of 18 patients was studied in which cefmenoxime regimens were adjusted prospectively to ensure success; 23 of 31 pathogens were eradicated from the sputum. Twenty-two of 23 organisms for which T>MIC for cefmenoxime was 100% were eradicated, compared with only 1 of 8 organisms for which T>MIC was less than 100%. 49 In 8 were associated with a favorable outcome in infected neutropenic patients treated with 13-lactams.13,14 However, one of these studies also showed that the trough SBT was predictive of efficacy.13 The inability to effectively distinguish between peak and trough SBT in predicting outcome also exists for studies of patients with endocarditis and osteomyelitis.11,12 This is because of the interdependence of pharmacokinetic parameters inherent whenever a fixed dosing interval is used; higher serum concentrations and/or more sensitive organisms translate both into higher peak and trough SBTs. In summary, although results from studies in in vitro and animal models suggest that frequent dosing with p-lactams to maintain continuous antibacterial in serum will contribute to efficacy, few confirmatory studies have been performed in humans. The higher intrinsic activity and longer serum half-lives of newer 13-lactams have permitted successful use of intermittent schedules with these agents, so that continuous infusion of islactams is usually unnecessary. However, the MIC still serves as a useful endpoint by which to judge the maximum dosing interval that may be used. Consequently, the potential for failure still exists when p-lactams are administered at intervals that allow for sustained periods of subinhibitory activity (i.e., use of very long intervals or conventional intervals for moderately susceptible bacteria).
Aminoglycosides and Quinolones: In vitro Models
In vitro dilution models have also been used extensively to study the role of dosing regimen in efficacy of the aminoglycosides and quinolones. Gerber and colleagues demonstrated that continuous infusion of a given dose of gentamicin over a 24-hour period against P aeruginosa was of equal efficacy to the same dose divided and given as three injections every eight hours.54 Similar findings for netilmicin were reported by Blaser, who noted equal efficacy whether the drug was administered as a continuous infusion, divided into eight hourly injections or administered as a single injection.55,56 These studies suggest that the AUC is the most important determinant of efficacy for aminoglycosides, and that dosing frequency plays a minor role. Later studies by Blaser, with netilmicin and enoxacin, demonstrated better results with single compared with multiple daily injections, suggesting that achieving a certain peak serum concentration may also be important. 56 The major contribution of higher peak concentrations was the prevention of regrowth of resistant organisms; this is a common problem with in vitro models, but may also occur in vivo. 41 Based on the concentration-dependent bactericidal activity and postantibiotic effects observed with aminoglycosides and quinolones, it would appear that attaining adequate peak concentrations of these agents would be of more importance for efficacy than the need to maintain active predose (trough) serum concentrations. Human studies performed to determine optimal dosing regimens of aminoglycosides and quinolones have attempted to define the appropriate serum concentration values needed for efficacy, but have been retrospective in design. Moore and colleagues and others have examined the role of serum concentrations of aminoglycosides in predicting therapeutic outcome. In patients with gram-negative bacteremia, peak gentamicin or amikacin levels greater than 5 or 20 mcg/ml, respectively, are associated with a higher response rate.15 For gram-negative bacterial pneumonia, critical values are greater than 7 or 28 mcg/ml, respectively.16 Later studies have concluded a peak concentration:MIC ratio of greater than 8:1 for aminoglycosides is predictive of success.17,62 The problems associated with these studies have again been associated with the interdependence of pharmacokinetic parameters. Because the aminoglycoside dosing interval was fixed at eight hours in the studies by Moore and colleagues, higher peak concentrations were likely to be associated with higher trough and AUC values as well, obscuring which parameter is of primary importance. In addition, these serum concentration guidelines reflect the use of aminoglycosides as monotherapy to treat gram-negative bacterial infections in these studies; it is conceivable that lower concentrations of aminoglycosides could be efficacious when used in combination with plactams. Finally, while the relationship of serum concentration to bacterial sensitivity is addressed in these studies, no consideration is given to the type of organism being treated, which may also be an important variable in determining response.
Schentag and colleagues retrospectively analyzed the role of pharmacokinetic parameters in predicting efficacy of ciprofloxacin in treating nosocomial bacterial pneumonia.63 In this study, T>MIC was cited as being the most important parameter associated with eradication of organisms. However, AUC and peak concentration were also highly correlated with outcome, therefore preventing identification of any one important parameter.
While it appears that a certain level of antimicrobial activity in serum is necessary to ensure efficacy of aminoglycosides and quinolones, the lack of data demonstrating superiority of continuous versus intermittent schedules suggests that dosing frequency is of much lesser importance for these agents than for the 13-lactams.
One of the most promising applications of basic studies in antibiotic pharmacodynamics has been the increasing use of once-daily aminoglycoside dosing.64-69 Many investigators are now reporting results of studies comparing conventional dosing regimens (every eight or 12 hours) of aminoglycosides with regimens administering the same total daily dose as a single injection. These studies have demonstrated equal efficacy and similar or less toxicity with the once-daily regimens. The majority of these studies have been performed in nonneutropenic patients and have involved combination therapy with 13-lactams. However, additional clinical trials, including those in neutropenic patients, are currently in progress. It is anticipated that as newer dosing regimens of antimicrobials gain popularity, additional investigations will be necessary to define appropriate laboratory parameters to ensure their safe and effective use.
Studies With Other Antimicrobials
Recently, investigators have begun to examine the use of different modes of administration for other classes of antibiotics, albeit often in an anecdotal and uncontrolled fashion. Pizzo and colleagues7o and Fletcher and associates71 have reported therapeutic success with use of continuous infusions of the antiviral compounds zidovudine and acyclovir, respectively; the latter used to treat patients with Herpes zoster infection that had been unresponsive to intermittent therapy. However, the total daily dose of acyclovir that was used with continuous infusion was higher than for previous regimens, so determining the role of dosing frequency alone was not possible. Whether or not the antiviral compounds exhibit concentration-depend-ent antimicrobial activity or a PAE is not known. Because of the narrow therapeutic window of many antiviral compounds, these agents may very well serve as the next target for pharmacodynamic studies leading to safer, more effective dosing regimens.
